Duke Pathology Blog

Should Biobanks be held to a Clinical Quality Standard?

Should Biobanks be held to a Clinical Quality Standard?

Should Biobanks be held to a Clinical Quality Standard?

Shannon McCall, MD,  Associate Professor and Director of the BioRepository & Precision Pathology Center (BRPC) is featured in a Mendelspot Science Podcast episode on this topic.  Mendelspod is a weekly podcast covering the frontiers of biomedical research including precision medicine, proteomics, clinical trials and new diagnostic technologies.  The podcast is sponsored by Scientist.com, a leader in scientific sourcing for the world’s top research organizations including NIH, Bristol-Myers Squibb, Novartis and AstraZeneca.  This summer Mendelspod has designed a series of podcasts focused on improving quality in biomedical research.  Dr. McCall discusses her experiences around specimen quality both in biobanking and in her role as pathologist and research collaborator in an academic medical center.  She discusses the idea of having biobanks meet clinical (CLIA)-equivalent standards of quality as a way to ensure that tomorrow’s diagnostic testing is built upon a solid scientific framework.
The BRPC shared resource is a College of American Pathologists-accredited Biorepository that works in partnership with the Clinical Laboratories at Duke University Health System including Duke University Hospital and Duke Regional Hospital.  Over 5,000 Duke patients have elected to contribute samples to the BRPC general bank, and BRPC handles thousands of other Duke patient samples in support of dedicated clinical trials.  Learn more at http://pathology.duke.edu/brpc.